TransMedics Group (TMDX)
TransMedics Group on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as electromedical & electrotherapeutic apparatus.
8.6M
Short interest
settlement 2026-09-30
13.1
Days to cover
+2.4 days vs prior
55.1%
Short share of volume
2026-10-09
31,021
Fails to deliver
settlement 2026-09-11
Wed 28 Oct
Next earnings
estimated date
$109K
Insider flow, 90 days
1 buys, 0 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in TMDX is 8,551,869 shares, up 472,782 shares over the last month. Over the last 48 readings it ranged from 6,439,780 shares (15 October 2024) to 11,129,933 shares (31 January 2025). At the reported average volume of 655K shares a day that is 13.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tmdx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 8,551,869 | +7.2% | 654,562 | 13.07 |
| 2026-09-15 | 7,977,125 | -1.3% | 747,124 | 10.68 |
| 2026-08-31 | 8,079,087 | +2.1% | 632,347 | 12.78 |
| 2026-08-14 | 7,910,244 | +3.1% | 1,179,701 | 6.71 |
| 2026-07-31 | 7,672,830 | -0.6% | 807,866 | 9.50 |
| 2026-07-15 | 7,715,332 | -1.9% | 809,077 | 9.54 |
| 2026-06-30 | 7,865,697 | +2.4% | 1,301,889 | 6.04 |
| 2026-06-15 | 7,680,998 | +4.4% | 1,065,864 | 7.21 |
| 2026-05-29 | 7,356,977 | -10.0% | 1,381,681 | 5.32 |
| 2026-05-15 | 8,178,039 | -1.7% | 2,419,508 | 3.38 |
| 2026-04-30 | 8,319,639 | +9.4% | 965,875 | 8.61 |
| 2026-04-15 | 7,606,337 | -5.3% | 740,723 | 10.27 |
| 2026-03-31 | 8,030,292 | -3.6% | 1,154,913 | 6.95 |
| 2026-03-13 | 8,330,878 | -1.7% | 890,419 | 9.36 |
| 2026-02-27 | 8,478,217 | +3.1% | 872,807 | 9.71 |
| 2026-02-13 | 8,225,157 | +4.2% | 582,235 | 14.13 |
| 2026-01-30 | 7,891,400 | +8.4% | 854,728 | 9.23 |
| 2026-01-15 | 7,280,097 | +1.1% | 709,542 | 10.26 |
| 2025-12-31 | 7,201,077 | +2.9% | 632,947 | 11.38 |
| 2025-12-15 | 6,996,469 | -9.3% | 772,855 | 9.05 |
| 2025-11-28 | 7,716,642 | +12.5% | 960,574 | 8.03 |
| 2025-11-14 | 6,860,927 | -9.0% | 786,531 | 8.72 |
| 2025-10-31 | 7,542,390 | -5.4% | 1,152,751 | 6.54 |
| 2025-10-15 | 7,971,237 | -2.1% | 865,357 | 9.21 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of TMDX volume is 55.1%, up 6.0 points over the last five sessions. Over the last 30 readings it ranged from 32.0% (6 October 2026) to 73.7% (1 September 2026). The latest reading is in line with the 30-session average of 56.3%, on 317K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 175K | 317K | 55.1% | 464 |
| 2026-10-08 | 243K | 401K | 60.5% | 4 |
| 2026-10-07 | 213K | 392K | 54.3% | 54,525 |
| 2026-10-06 | 84K | 264K | 32.0% | 138 |
| 2026-10-05 | 202K | 369K | 54.6% | 1,001 |
| 2026-10-02 | 279K | 568K | 49.2% | 61 |
| 2026-10-01 | 201K | 419K | 48.0% | 889 |
| 2026-09-30 | 114K | 241K | 47.1% | 61 |
| 2026-09-29 | 105K | 194K | 54.2% | 0 |
| 2026-09-28 | 76K | 179K | 42.3% | 110 |
| 2026-09-25 | 151K | 323K | 46.9% | 0 |
| 2026-09-24 | 144K | 270K | 53.3% | 1,337 |
| 2026-09-23 | 157K | 278K | 56.4% | 5 |
| 2026-09-22 | 196K | 370K | 53.0% | 231 |
| 2026-09-21 | 131K | 245K | 53.4% | 0 |
| 2026-09-18 | 150K | 256K | 58.4% | 6 |
| 2026-09-17 | 182K | 329K | 55.3% | 0 |
| 2026-09-16 | 123K | 188K | 65.3% | 2 |
| 2026-09-15 | 281K | 456K | 61.7% | 560 |
| 2026-09-14 | 200K | 384K | 52.1% | 420 |
| 2026-09-11 | 353K | 574K | 61.5% | 800 |
| 2026-09-10 | 150K | 231K | 65.0% | 925 |
| 2026-09-09 | 181K | 264K | 68.4% | 89 |
| 2026-09-08 | 119K | 197K | 60.3% | 11 |
| 2026-09-04 | 131K | 188K | 69.9% | 100 |
| 2026-09-03 | 139K | 216K | 64.1% | 59 |
| 2026-09-02 | 122K | 197K | 61.7% | 503 |
| 2026-09-01 | 234K | 318K | 73.7% | 1,399 |
| 2026-08-31 | 285K | 473K | 60.2% | 88 |
| 2026-08-28 | 134K | 257K | 52.1% | 7,181 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 11 September 2026, the fails-to-deliver balance in TMDX is 31,021 shares, up 29,285 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (4 September 2026) to 98,071 shares (25 August 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-11 | 31,021 | $85.04 | $2.6M |
| 2026-09-08 | 1,736 | $89.98 | $156K |
| 2026-09-04 | 1 | $86.98 | $87 |
| 2026-09-02 | 24 | $82.24 | $2K |
| 2026-08-26 | 5 | $93.60 | $468 |
| 2026-08-25 | 98,071 | $93.60 | $9.2M |
| 2026-08-24 | 4,431 | $94.77 | $420K |
| 2026-08-17 | 109 | $88.58 | $10K |
| 2026-08-14 | 38 | $89.64 | $3K |
| 2026-08-13 | 39,375 | $87.02 | $3.4M |
| 2026-08-11 | 2,640 | $88.41 | $233K |
| 2026-08-07 | 938 | $80.21 | $75K |
| 2026-07-29 | 1,379 | $76.29 | $105K |
| 2026-07-28 | 58,496 | $74.28 | $4.3M |
| 2026-07-27 | 61,353 | $72.26 | $4.4M |
| 2026-07-22 | 192 | $74.29 | $14K |
| 2026-07-20 | 6,827 | $73.98 | $505K |
| 2026-07-16 | 12 | $75.38 | $905 |
| 2026-07-14 | 1,096 | $75.74 | $83K |
| 2026-07-13 | 847 | $71.23 | $60K |
| 2026-07-07 | 15 | $71.23 | $1K |
| 2026-06-26 | 206 | $77.75 | $16K |
| 2026-06-25 | 292 | $77.62 | $23K |
| 2026-06-24 | 161 | $73.83 | $12K |
| 2026-06-23 | 269 | $75.51 | $20K |
| 2026-06-22 | 200 | $78.79 | $16K |
| 2026-06-15 | 576 | $72.91 | $42K |
| 2026-06-11 | 14 | $74.77 | $1K |
| 2026-06-08 | 52 | $69.43 | $4K |
| 2026-06-03 | 1,759 | $68.45 | $120K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at TMDX reported 1 open-market buy worth $109K in the last 90 days and no open-market sells. Latest filing: Weill David (Director) on 2026-09-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Weill David | Director | Buy | 1K | $81.63 | $109K | 16K |
| 2026-08-17 | TOBIN JAMES R | Director | Gift | 18K | $0.00 | $0 | 0 |
| 2026-07-10 | Hernandez Gerardo | Chief Financial Officer | Grant | 17K | $0.00 | $0 | 32K |
| 2026-07-10 | Hassanein Waleed H | President & CEO | Grant | 50K | $0.00 | $0 | 171K |
| 2026-07-10 | Corcoran Nicholas | See remarks | Grant | 12K | $0.00 | $0 | 42K |
| 2026-06-15 | Gunderson Thomas J. | Director | Sell | 10K | $75.06 | $722K | 17K |
| 2026-06-15 | Gunderson Thomas J. | Director | Option exercise | 19K | $2.21 | $43K | 26K |
| 2026-05-20 | Weill David | Director | Grant | 3K | $0.00 | $0 | 15K |
| 2026-05-20 | TOBIN JAMES R | Director | Grant | 3K | $0.00 | $0 | 7K |
| 2026-05-20 | RAINES MERILEE | Director | Grant | 3K | $0.00 | $0 | 7K |
| 2026-05-20 | Lovell Stephanie | Director | Grant | 3K | $0.00 | $0 | 6K |
| 2026-05-20 | Kania Edwin | Director | Grant | 3K | $0.00 | $0 | 264K |
| 2026-05-20 | Gunderson Thomas J. | Director | Grant | 3K | $0.00 | $0 | 7K |
| 2026-05-20 | Basile Edward M | Director | Grant | 3K | $0.00 | $0 | 6K |
| 2026-05-19 | Forsyth Matthew S. | See Remarks | Grant | 15K | $0.00 | $0 | 15K |
| 2026-03-04 | Hernandez Gerardo | Chief Financial Officer | Sell | 6K | $147.21 | $870K | 15K |
| 2026-03-04 | Hernandez Gerardo | Chief Financial Officer | Option exercise | 6K | $69.84 | $413K | 21K |
| 2026-03-04 | Hernandez Gerardo | Chief Financial Officer | Sell | 1K | $147.21 | $195K | 15K |
| 2026-03-04 | Hernandez Gerardo | Chief Financial Officer | Option exercise | 1K | $77.12 | $102K | 16K |
| 2026-03-04 | Weill David | Director | Sell | 4K | $146.82 | $524K | 12K |
| 2026-03-04 | Weill David | Director | Option exercise | 4K | $14.20 | $51K | 16K |
| 2026-03-04 | Lovell Stephanie | Director | Sell | 1K | $149.62 | $178K | 3K |
| 2026-03-02 | Ranganath Anil P. | See remarks | Sell | 864 | $139.12 | $120K | 13K |
| 2026-03-02 | Hernandez Gerardo | Chief Financial Officer | Sell | 375 | $139.12 | $52K | 15K |
| 2026-03-02 | Corcoran Nicholas | See remarks | Sell | 3K | $139.12 | $413K | 30K |
| 2026-02-18 | Cecere Giovanni | Chief Commercial Officer | Grant | 11K | $0.00 | $0 | 19K |
| 2026-01-23 | Corcoran Nicholas | See remarks | Tax withholding | 984 | $135.30 | $133K | 33K |
| 2025-12-04 | Hernandez Gerardo | Chief Financial Officer | Sell | 920 | $139.62 | $128K | 15K |
| 2025-12-03 | Weill David | Director | Sell | 5K | $138.64 | $693K | 12K |
| 2025-12-03 | Weill David | Director | Option exercise | 5K | $14.20 | $71K | 17K |
| 2025-11-25 | Ranganath Anil P. | See remarks | Sell | 3K | $145.22 | $436K | 14K |
| 2025-11-25 | Ranganath Anil P. | See remarks | Option exercise | 3K | $93.88 | $282K | 17K |
| 2025-11-17 | Hassanein Waleed H | President & CEO | Buy | 9K | $114.00 | $1.0M | 495K |
| 2025-10-29 | Basile Edward M | Director | Sell | 4K | $130.45 | $540K | 3K |
| 2025-10-29 | Basile Edward M | Director | Option exercise | 4K | $0.70 | $3K | 7K |
| 2025-08-07 | Hassanein Waleed H | President & CEO | Buy | 2K | $116.85 | $217K | 486K |
| 2025-08-07 | Hassanein Waleed H | President & CEO | Buy | 7K | $116.08 | $768K | 484K |
| 2025-08-06 | Hassanein Waleed H | President & CEO | Buy | 8K | $118.68 | $997K | 478K |
| 2025-08-04 | Basile Edward M | Director | Sell | 4K | $125.51 | $520K | 3K |
| 2025-08-04 | Basile Edward M | Director | Option exercise | 4K | $0.70 | $3K | 7K |
| 2025-06-09 | Ranganath Anil P. | See remarks | Sell | 686 | $139.80 | $96K | 14K |
| 2025-05-27 | Basile Edward M | Director | Sell | 5K | $126.45 | $632K | 3K |
| 2025-05-27 | Basile Edward M | Director | Option exercise | 5K | $0.70 | $4K | 8K |
| 2025-05-23 | Weill David | Director | Sell | 732 | $123.88 | $91K | 12K |
| 2025-05-22 | Weill David | Director | Grant | 2K | $0.00 | $0 | 13K |
| 2025-05-22 | KANIA EDWIN M JR | Director | Grant | 2K | $0.00 | $0 | 261K |
| 2025-05-22 | Gunderson Thomas James | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2025-05-22 | RAINES MERILEE | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2025-05-22 | TOBIN JAMES R | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2025-05-22 | Lovell Stephanie | Director | Grant | 2K | $0.00 | $0 | 4K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON7 Form 144 notices on file for TMDX worth $4.2M at the prices reported; 0 in the last 90 days worth $0. Latest: THOMAS GUNDERSON filed on 2026-06-15 to sell 9,624 shares ($722K) from 2026-06-15.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-15 | THOMAS GUNDERSONDirector | 10K | $722K | 0.028% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | DAVID WEILLDirector | 4K | $524K | 0.010% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | STEPHANIE LOVELLDirector | 1K | $178K | 0.003% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | GERARDO P HERNANDEZOfficer | 7K | $1.1M | 0.021% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-03 | DAVID WEILLDirector | 5K | $693K | 0.015% | 2025-12-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-25 | ANIL P RANGANATHOfficer | 3K | $436K | 0.009% | 2025-11-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-29 | EDWARD BASILEDirector | 4K | $540K | 0.012% | 2025-10-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of TMDX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 5.7% of the class (1,949,420 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 1.7M | 5.1% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Portfolio Managementinvestment adviser | 1.9M | 5.7% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding TMDX at their latest 13F. JSON5 of the 30 tracked managers held TMDX at their latest 13F, $68.9M in total at quarter-end prices. Citadel Advisors is the largest at $37.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 559K | $37.1M | 0.00% | +497K |
| Millennium Management | 2026-06-30 | 248K | $16.5M | 0.01% | -58K |
| Point72 Asset Management | 2026-06-30 | 193K | $12.8M | 0.01% | new |
| AQR Capital Management | 2026-06-30 | 28K | $1.9M | 0.00% | +20K |
| Two Sigma Investments | 2026-06-30 | 9K | $594K | 0.00% | -316K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) TransMedics Group reported revenue of $189.9M, up 20.7% from the same quarter a year earlier, and net income of $14.7M (0.41 diluted EPS). In FY 2025 it generated $192.8M of operating cash flow.
- Equity
- $518.1M
- Total assets
- $1.46B
- Shares outstanding
- 34,675,145
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $189.9M | $14.7M | 7.7% | 0.41 |
| Q1 FY 2026 | 2026-03-31 | $173.9M | $7.3M | 4.2% | 0.20 |
| Q4 FY 2025derived | 2025-12-31 | $160.8M | $105.4M | 65.6% | n/a |
| Q3 FY 2025 | 2025-09-30 | $143.8M | $24.3M | 16.9% | 0.66 |
| Q2 FY 2025 | 2025-06-30 | $157.4M | $34.9M | 22.2% | 0.92 |
| Q1 FY 2025 | 2025-03-31 | $143.5M | $25.7M | 17.9% | 0.70 |
| Q4 FY 2024derived | 2024-12-31 | $121.6M | $6.9M | 5.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $108.8M | $4.2M | 3.9% | 0.12 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $605.5M | $190.3M | $192.8M | $59.3M | n/a | n/a |
| FY 2024 | 2024-12-31 | $441.5M | $35.5M | $48.8M | $129.7M | n/a | n/a |
| FY 2023 | 2023-12-31 | $241.6M | -$25.0M | -$13.0M | $151.8M | n/a | n/a |
| FY 2022 | 2022-12-31 | $93.5M | -$36.2M | -$45.8M | $11.9M | n/a | n/a |
| FY 2021 | 2021-12-31 | $31.4M | -$44.2M | -$28.9M | $3.5M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.
What this page is
TransMedics Group in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows TransMedics Group (TMDX), SEC CIK 1756262, listed on Nasdaq, classified by the SEC as electromedical & electrotherapeutic apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-11.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1756262Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as electromedical & electrotherapeutic apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of TMDX is sold short?
What is TMDX's daily short volume?
Does TMDX have fails to deliver?
Are TMDX insiders buying or selling?
Have TMDX insiders filed to sell?
Who owns 5% or more of TMDX?
What did TMDX report last quarter?
Which tracked 13F managers own TMDX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.